FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
1,091 letters match. Newest first.
-
DrugsShree Jaya Laboratories PVT. LTD.
FDA warned Shree Jaya Laboratories after an inspection found CGMP deviations in API and intermediate manufacturing, including dirty equipment and torn batch records.
High risk -
DrugsLinghai ZhanWang Biotechnology Co., Ltd
Linghai ZhanWang Biotechnology's OTC drugs, including antimicrobial wipes, fail manufacturing quality rules; FDA cites missing tests.
High risk -
DrugsRight Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals
FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.
High risk -
DrugsProRx, LLC
FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.
High risk -
DrugsGranules India Limited
FDA warned Granules India in Telangana, India, that its finished drugs are adulterated after inspectors found cross-contamination in air ducts, bird droppings and torn records.
High risk -
DrugsChem-Tech, Ltd.
Chem-Tech, Ltd. lacked adequate investigations and clean equipment for its OTC drug.
High risk -
FoodMariscos Procesados - CAMPRESA - S.A.
Mariscos Procesados-CAMPRESA's frozen vacuum-packed mahi-mahi fillets lacked required seafood HACCP controls, FDA says.
High risk -
DrugsZenzi Pharmaceutical Industries Pvt. Ltd.
Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.
High risk -
DrugsMarshalls Traditional Healthcare CC
Marshalls Traditional Healthcare, an OTC drug maker in South Africa, lacked finished-product release testing and process validation.
High risk -
DrugsABR Laboratory LLC
FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.
High risk -
DrugsTyche Industries Ltd
FDA warned Tyche Industries over falsified records, dirty equipment, and untested raw materials at its API plant.
High risk -
DrugsJagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.
High risk -
DrugsAmWiner & Raphe Holdings, LLC dba rapheGenerics Corp
FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.
High risk -
DrugsChengdu Innovation Pharmaceutical Co., Ltd.
FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.
High risk -
DrugsWuhu Nuowei Chemistry Co., Ltd.
FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.
High risk -
DrugsStrukmyer LLC dba Strukmyer Medical
Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.
High risk -
DrugsShantou Kangjie Daily Chemical Industry Co., Ltd
FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.
High risk -
DrugsImperial Palace Commodity -Dongguan- Co., Ltd.
FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.
High risk -
DrugsCenter for Instrumental Analysis of China Pharmaceutical University
Center for Instrumental Analysis of China Pharmaceutical University cited for incomplete API testing records and no quality unit.
High risk -
BiologicsBioStem Life Sciences
FDA says BioStem Life Sciences made unapproved umbilical cord and amniotic products with significant CGMP violations.
High risk -
DrugsGlobal Calcium Pvt. Limited
FDA cites Global Calcium API plant for falsified records, deleted files, facility leaks and incomplete impurity profiles; products on Import Alert 66-40.
High risk -
DrugsFagron Compounding Services, LLC dba Fagron Sterile Service
FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.
High risk -
DrugsKardesler Ucan Yaglar Sanayi Anonim Sirketi
Turkey-based OTC drug maker Kardesler Ucan failed to test glycerin, propylene glycol and ethanol for dangerous impurities and is on US import alert.
High risk -
BiologicsChara Biologics, Inc.
FDA warns Chara Biologics over unapproved, unlicensed CharaExo, CharaCore, CharaOmni.
High risk -
DrugsSanofi
FDA warned Sanofi subsidiary Genzyme over manufacturing quality failures at its Framingham, MA API plant.
High risk -
DrugsAtlanta Supersource, Inc.
Atlanta Supersource made OTC hand sanitizers on equipment shared with toxic industrial chemicals and lacked testing, FDA says.
High risk -
FoodNyumbani Hakuna Matata LLC
FDA warns Buffalo seafood importer Nyumbani Hakuna Matata over missing safety checks for dried fish from Tanzania.
High risk -
FoodCOFISA - Conservas de Peixe da Figueira, S.A.
FDA found COFISA's canned sardine and tuna food-safety plans inadequate, with missing hazards and weak histamine (spoilage toxin) controls.
High risk -
DrugsINCELL Corporation LLC
FDA warned INCELL Corporation for making an unapproved amniotic-fluid drug without validating its sterile manufacturing process.
High risk -
FoodDuong Ha Processing Trading Seafood Company Limited
FDA warns Vietnam seafood processor Duong Ha over HACCP failures for frozen scombrotoxin-forming fish.
High risk -
FoodSalt City Baking Company, LLC
FDA says Salt City Baking's ready-to-eat bread was made under insanitary conditions, with insects, mold and missing food-safety controls.
High risk -
FoodWestern Innovations, Inc.
FDA warns Western Innovations over manufacturing-rule violations in Acetyl-glutathione supplements after Denver inspection.
Medium -
DevicesIntegra LifeSciences Corporation
FDA warned Integra LifeSciences over bacterial toxin test and sterilization failures at three medical device plants.
High risk -
DevicesHologic, Inc.
FDA warns Hologic over design-control and reporting failures for implantable BioZorb markers, including missed medical device reports and a correction report.
High risk -
DevicesXoran Technologies, LLC
FDA warned Xoran Technologies that its computed tomography devices and software violate quality rules and lack required marketing clearance.
High risk -
DevicesPhillips Precision, Inc.
FDA says Phillips Precision, a contract maker of orthopedic implants and instruments, violated device quality rules for cleaning and process controls.
High risk -
DevicesRandox Laboratories Limited
FDA warned Randox Laboratories over inadequate risk analysis and corrective actions for carryover errors in RX series analyzers.
High risk -
DrugsIndoco Remedies Limited
FDA warned Indoco Remedies over manufacturing quality failures at its Goa plant, including unreliable microbial testing and aseptic processing deficiencies.
High risk -
BiologicsXO Biologix, LLC
XO Biologix markets MaviX, an amniotic-fluid product, as an unapproved new drug and unlicensed biologic.
High risk -
FoodGuangzhou Sinocon Food Co., Ltd
FDA warns Guangzhou Sinocon Food over food-safety violations in ready-to-eat Oat Beta Glucan powder, including pathogen hazards and inaccurate test certificates.
High risk -
DrugsBhargava Phytolab Private Limited
FDA warns Bhargava Phytolab over drug and API current good manufacturing practice (CGMP) violations, including inadequate testing and sterility controls.
High risk -
DrugsViatris, Inc.
FDA warns Viatris that its Indore, India, drug plant had unreliable quality data and weak investigations.
High risk -
DrugsSombra Cosmetics, Inc.
FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.
High risk -
DrugsAkron Formulations India Private Limited
Akron Formulations India's over-the-counter drugs are adulterated due to manufacturing quality (CGMP) failures, including unqualified active ingredient (API) suppliers and inadequate microbial testing.
High risk -
DrugsBrands International Corporation
Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.
High risk -
DevicesRontis Hellas S.A.
Rontis Hellas made Cronus HP PTA balloon catheters with an unproven EtO sterilization process and inadequate US adverse-event reporting procedures.
High risk -
DrugsMicro Orgo Chem
Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.
High risk -
DevicesBecton, Dickinson, and Company/CareFusion 303, Inc.
FDA warned Becton Dickinson/CareFusion over Pyxis medication dispensing systems with unresolved software defects, missed MDR reports and unreported recalls.
High risk -
AnimalMid America Pet Food LLC
FDA warned Mid America Pet Food after Salmonella-linked recalls and found persistent contamination and animal-food safety-rule violations at its Texas plant.
High risk -
DrugsDr. Brite, LLC
FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.
High risk